Fulgent Genetics (FLGT) COO reports 4,711-share tax withholding event

Rhea-AI Filing Summary

Fulgent Genetics, Inc. President and COO Jian Xie reported a tax-related share withholding on common stock. On January 26, 2026, 4,711 shares of Fulgent Genetics common stock were withheld at $27.53 per share to cover tax obligations from the vesting of restricted stock units tied to a prior merger agreement.

After this transaction, Xie directly beneficially owns 332,038 common shares. In addition, 220,816 common shares are reported as indirectly owned through The Hsieh Family Dynasty Trust, where Xie serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Xie Jian

Role President and COO

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	4,711	$27.53	$130K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 332,038 shares (Direct); Common Stock — 220,816 shares (Indirect, By Trust)

Footnotes (1)

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xie Jian

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CA 91731

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		F		4,711(1)	D	$27.53	332,038	D
Common Stock								220,816	I	By Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.

2. Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.

	/s/ Paul Kim as Attorney-in-Fact	01/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Fulgent Genetics (FLGT) report for Jian Xie?

Fulgent Genetics reported that President and COO Jian Xie had 4,711 common shares withheld to cover tax obligations. The withholding occurred on January 26, 2026, in connection with vesting restricted stock units that were originally assumed under a prior merger agreement involving Fulgent Pharma Holdings.

How many Fulgent Genetics (FLGT) shares were withheld for taxes and at what price?

The filing shows 4,711 Fulgent Genetics common shares were withheld to satisfy tax withholding obligations. These shares were valued at a price of $27.53 per share, and the withholding related to the vesting of restricted stock units originally reported on a November 9, 2022 Form 4.

How many Fulgent Genetics (FLGT) shares does Jian Xie own directly after the transaction?

After the January 26, 2026 transaction, Jian Xie directly beneficially owns 332,038 Fulgent Genetics common shares. This direct holding figure reflects the position following the tax-related share withholding tied to vesting restricted stock units assumed under an earlier merger agreement.

What Fulgent Genetics (FLGT) shares are reported as indirectly owned by Jian Xie?

The filing reports 220,816 Fulgent Genetics common shares as indirectly owned through The Hsieh Family Dynasty Trust. Jian Xie serves on the Trust’s investment committee and disclaims beneficial ownership of these shares, except to the extent of any pecuniary interest he may have in the Trust assets.

What is the nature of the restricted stock units involved for Fulgent Genetics (FLGT)?

The restricted stock units that triggered tax withholding were assumed under an Agreement and Plan of Merger dated November 7, 2022. That merger involved Fulgent Genetics, FG Merger Sub, Fulgent Pharma Holdings, and certain stockholders, and the awards were originally reported on a November 9, 2022 Form 4.

What role does Jian Xie hold at Fulgent Genetics (FLGT) in this Form 4 filing?

In this Form 4, Jian Xie is identified as an officer of Fulgent Genetics, serving as President and Chief Operating Officer. The filing reflects his status as a reporting person for insider transactions in the company’s common stock under U.S. securities regulations.